Product Description
a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402822/)
Mechanisms of Action: HP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Japan
Approved Indications: None
Company: Astellas Pharma
Company Location:
Company Founding Year: 2005
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
JapicCTI-184242 |
JapicCTI-184242 | P1 |
Active |
Unknown |
2019-11-30 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/31/2020 |
News Article |
Global Herpes Labialis (Oral Herpes) Pipeline Guide H1, 2020 - ResearchAndMarkets.com |